This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 28 May 2024
2 min

Multiple Sclerosis

Author: Sanofi

Editorial Team

 Sanofi's history in MS
futuristic image of human brain

At Sanofi, we have a rich history of MS research and treatment dating back to the 1970s. Through our partnership with Cambridge University, we have been at the forefront of delivering breakthrough medications to patients. Our commitment to patients and our passion for innovation in neurological disorders, such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and others, remains a top priority and investment for us.

We are driven by the desire to understand the science behind diseases like MS, which motivates us to challenge our assumptions and offer innovative solutions to meet the unmet needs of people affected by these conditions. With ongoing research into various treatments, we invite healthcare professionals to stay tuned for further updates and information later this year!

brain fire

Thank you for visiting our Neurology page, and we look forward to your continued engagement and collaboration in advancing patient care.

MAT-XU-2402078 (v1.0) Date of Preparation: June 2024